Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
Download PDF
CC BY-NC-ND 4.0 · Nuklearmedizin 2024; 63(06): 328-336
DOI: 10.1055/a-2353-5819
DOI: 10.1055/a-2353-5819
Review
Die moderne TARE 2023 – von der Palliativversorgung zur kurativen Behandlungsalternative
Modern TARE 2023 – from palliative care to a curative treatment alternativeAuthors
Supported by: LinkCare GmbH
Supported by: SIRTEX Medical Europe GmbH
Zusammenfassung
Die selektive interne Radiotherapie (SIRT) oder transarterielle Radioembolisation (TARE) ist eine Behandlungsalternative beim hepatozellulären Karzinom (HCC) oder hepatisch metastasierten kolorektalen Karzinom (mCRC) und ist mittlerweile in vielen Leitlinien verankert. Der Artikel fasst die aktuellen Leitlinien zur SIRT/TARE beim HCC bzw. mCRC zusammen.
Abstract
Selective internal radiotherapy (SIRT) or transarterial radioembolisation (TARE) is an alternative treatment for hepatocellular carcinoma (HCC) or hepatic metastatic colorectal carcinoma (mCRC) and is now anchored in many guidelines. The article summarises the current guidelines on SIRT/TARE in HCC and mCRC.
* Shared Senior Authorship
Publication History
Received: 05 December 2023
Accepted after revision: 13 May 2024
Article published online:
16 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Referenzen
- 1 Teichgräber U, Gebauer B. Correction: Radioembolisation mit Yttrium-90-Mikrosphären. Der Onkologe 2017; 23 (11) 951-60
- 2 Miller FH, Lopes Vendrami C, Gabr A. et al. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021; 41 (06) 1802-1818
- 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome Langversion 3.0, 2022, AWMF-Registernummer: 032/053OL [Internet]. [zitiert 3. Januar 2024]. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome/
- 4 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76 (03) 681-693
- 5 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020; 30 (01) 68-76
- 6 Jeyarajah DR, Doyle MBM, Espat NJ. et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol 2020; 11 (02) 443-460
- 7 DʼAbadie P, Walrand S, Lhommel R. et al. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr Oncol 2022; 29 (04) 2422-2434
- 8 Galle PR, Forner A, Llovet JM. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
- 9 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016; 27 (08) 1386-1422
- 10 National Comprehensive Cancer Network. NCCN Guideline on Colon Cancer, Version 4.2023 [Internet]. [zitiert 3. Januar 2024]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428
- 11 Singal AG, Llovet JM, Yarchoan M. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023; 78 (06) 1922-1965
- 12 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL [Internet]. [zitiert 3. Januar 2024]. http://www.leitlinienprogrammonkologie.de/leitlinien/kolorektales-karzinom/
- 13 Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40 (02) 105-121
- 14 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, 2013, AWMF Registrierungsnummer: 032–053OL [Internet]. [zitiert 3. Januar 2024]. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
- 15 Salem R, Johnson GE, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74 (05) 2342-2352
- 16 Chapman WC, Garcia-Aroz S, Vachharajani N. et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224 (04) 610-621
- 17 Salem R, Gordon AC, Mouli S. et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
- 18 Ettorre GM, Levi Sandri GB, Laurenzi A. et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41 (01) 241-249
- 19 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29
- 20 Hermann AL, Dieudonné A, Ronot M. et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology 2020; 296 (03) 673-684
- 21 Gardini AC, Tamburini E, Iñarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321
- 22 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. ur Radiol 2017; 27 (05) 2031-2041
- 23 Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2016 Feb 16;2. Update in: Cochrane Database Syst Rev. 2020 Jan 24;1.
- 24 Gibbs P, Heinemann V, Sharma N. et al. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clin Colorectal Cancer 2018; 17 (04) e617-e629
- 25 Mulcahy MF, Mahvash A, Pracht M. et al. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021; 39 (35) 3897-3907
- 26 Garlipp B, Gibbs P, van Hazel GA. et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg 2019; 106 (13) 1837-1846
- 27 Llovet JM, Ducreux M, Lencioni R. et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Erratum in: J Hepatol. 2012 Jun;56(6):1430. J Hepatol 2012; 56 (04) 908-943
- 28 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA, ). Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karziome, Langversion 2.0, 2021, AWMF Registernummer: 032/053OL [Internet]. [zitiert 3. Januar 2024]. Verfügbar unter. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-billiäre-karzinome
- 29 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: A randomized trial. Endoscopy 2018; 50 (08) 751-760
- 30 van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
- 31 Hendlisz A, van den Eynde M, Peeters M. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
- 32 van Hazel G, Blackwell A, Anderson J. et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88 (02) 78-85
- 33 Palmer DH, Hawkins NS, Vilgrain V. et al. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol 2020; 16 (01) 4315-4325